NeoCOAST-2: A phase 2 study of neoadjuvant durvalumab plus novel immunotherapies (IO) and chemotherapy (CT) or MEDI5752 (volrustomig) plus CT, followed by surgery and adjuvant durvalumab plus novel IO or volrustomig alone in patients with resectable non-small-cell lung cancer (NSCLC).

Florian  Guisier

Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Janssen; MSD; Pfizer; Roche; Sanofi; Takeda

Consulting or Advisory Role - Amgen; AstraZeneca; BMS GmbH & Co. KG; MSD; Roche; Sanofi

Research Funding - Pfizer (Inst); Roche (Inst); Takeda (Inst)

Travel, Accommodations, Expenses - Amgen; MSD; Takeda

Jaafar  Bennouna

Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Daichii; Daichii; Ipsen; Janssen Oncology; MSD Oncology; Novartis; SERVIER

Consulting or Advisory Role - AMGEN; AstraZeneca; Bristol-Myers Squibb; MSD; Novartis; Roche; SERVIER

Research Funding - AstraZeneca (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche

Alexander I.  Spira

Leadership - Next Oncology (Inst)

Stock and Other Ownership Interests  - Lilly

Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda

Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda

Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)

Dong-Wan  Kim

Research Funding - Alpha Biopharma (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); BridgeBio Pharma (Inst); Chong Kun Dang Pharmaceutical (Inst); Daiichi Sankyo (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); inno.N (Inst); Janssen (Inst); Merck (Inst); Merus (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche/Genentech (Inst); Takeda (Inst); TP Therapeutics (Inst); Xcovery (Inst); Yuhan (Inst)

Byoung Yong  Shim

Consulting or Advisory Role - AstraZeneca; Bion; Guardant Health; J Ints Bio; Pfizer; Takeda

Research Funding - Yuhan

Houssein  Abdul Sater

Employment - Vision Integrity Precision; Vision Integrity Precision (I)

Italia  Grenga

No Relationships to Disclose

Swapnil S  Parmar

Employment - AstraZeneca/MedImmune; PRA Health Sciences

Agata A.  Bielska

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Alula  Yohannes

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Raymond  Mager

Employment - AstraZeneca

Oday  Hamid

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Lara  McGrath

Employment - AstraZeneca; Jounce Therapeutics

Stock and Other Ownership Interests  - AstraZeneca; Jounce Therapeutics

Patents, Royalties, Other Intellectual Property - Jounce Therapeutics

Yun  He

Employment - AstraZeneca

Stock and Other Ownership Interests  - AstraZeneca

Yee  Soo-Hoo

Employment - AstraZeneca/MedImmune

Stock and Other Ownership Interests  - AstraZeneca/MedImmune

Travel, Accommodations, Expenses - AstraZeneca/MedImmune

Rakesh  Kumar

Employment - AstraZeneca/MedImmune

Stock and Other Ownership Interests  - AstraZeneca

Jonathan  Spicer

Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb/Medarex; Chemocentryx; Merck; Novartis

Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck; Protalix Biotherapeutics; Regeneron; Xenetic Biosciences

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Medarex (Inst); CLS-Therapeutics (Inst); CLS-Therapeutics (Inst); Merck (Inst); Protalix Biotherapeutics (Inst); Roche (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/Medarex; Merck

Patrick M.  Forde

Consulting or Advisory Role - Amgen; Ascendis Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; CureVac; Daiichi Sankyo/UCB Japan; F-Star Biotechnology; Fosun Pharma; G1 Therapeutics; Genentech; Gilead Sciences; ITeos Therapeutics; Janssen; Merck; Novartis; Regeneron; Sanofi; Surface Oncology; Synthekine; Teva

Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals; Kyowa Hakko Kirin (Inst); Novartis (Inst); Regeneron

Tina  Cascone

Honoraria - Brystol-Myers Squibb; IDEOlogy Health; Mark Foundation for Cancer Research; Medscape; Onclive; Peerview; Roche; Society for Immunotherapy of Cancer

Consulting or Advisory Role - Arrowhead Pharmaceuticals; Bristol Myers Squibb; EMD Serono; Genentech; MedImmune; Merck; Regeneron

Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); MedImmune (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Dava Oncology; IASLC; IDEOlogy Health; Parker Institute for Cancer Immunotherapy; Society for Immunotherapy of Cancer